Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1293
- Registration Number
- NCT02248207
Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT02248883
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Low dose of BIIL 284 BS tabletsDrug: Medium dose of BIIL 284 BS tabletsDrug: High dose of BIIL 284 BS tabletsDrug: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 577
- Registration Number
- NCT02249247
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2644
- Registration Number
- NCT02248155
Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02245451
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3629
- Registration Number
- NCT02244268
Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: alpha-adrenergic blocker
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4561
- Registration Number
- NCT02244307
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
Phase 2
Completed
- Conditions
- Prostate Hyperplasia
- Interventions
- Drug: Placebo capsules
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 176
- Registration Number
- NCT02244294
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 982
- Registration Number
- NCT02245529
Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4575
- Registration Number
- NCT02244333